Avicidin

Avicidin

An investigational radioimmunotherapeutic agent for treating advanced therapeutically refractive cancers of the colon, ovarian and prostate, which delivers high-dose RT to metastatic tumours, while minimising exposure of normal tissues, especially bone marrow. Avicidin was discontinued in phase-II trials due to a high incidence of unacceptable diarrhea, which was atributed to cross-reactivity of the Avicidin anti-Epcam antibody with the intestine.
References in periodicals archive ?
NeoRx, Avicidin and Chemotides are trademarks or registered trademarks of NeoRx Corporation in the United States and/or foreign countries.
NeoRx, Avicidin, and Chemotide are trademarks or registered trademarks of NeoRx Corporation in the United States and/or foreign countries.
We believe that the decisions last year to discontinue the Avicidin and Biostent programs should not be viewed as an indictment of the core competencies and quality of the NeoRx team.
Under terms of the agreement, Janssen has agreed to conduct the clinical trials for Avicidin and, assuming other milestones are achieved, bring the new therapy to market worldwide.
NeoRx management and the Board are disappointed with the stock market's reaction to the cessation of the Company's Biostent and Avicidin partnerships" said Dr.
Also in the quarter, we announced an agreement with NeoRx for their oncology product Avicidin.
NeoRx's lead therapeutic products, Avicidin Cancer Therapy and Biostent, an agent designed to prevent restenosis after balloon angioplasty, are in Phase I clinical trials.
Avicidin is in Phase I/II clinical trials for solid tumors (lung, colon, breast and prostate) and employs NeoRx's proprietary Pretarget(TM) technology for delivering radiation therapy to tumor cells while minimizing exposure to normal tissue.
As we have previously announced, a single dose of Avicidin incorporating a mouse-derived antibody has, in early clinical trials, produced evidence of shrinkage of metastatic tumors in some of the patients with prostate, colon and ovarian cancers that had failed standard therapy.
Verluma, our first product, is now being marketed by DuPont Merck; recently announced Biostent results appear to indicate a clean safety profile, and our dose escalation study with Avicidin Cancer Therapy continues, showing evidence of anti tumor activity.
Their insight of separating the injections of the targeting agent and effector molecules, rather than loading the effector molecule onto the antibody, has already demonstrated that previously unheard of doses of radioactivity can be safely administered to patients, and that patients with bulky, advanced cancers that failed standard therapies can respond even to a single Avicidin dose.
Simultaneously, we are testing the humanized antibody in the clinic, and hope to substitute that antibody for the murine antibody currently in the Avicidin product.